FibroScan Results: 6.8 kPa LSM and 202 dB/m CAP
Your FibroScan shows no significant fibrosis (F0-F1) and mild steatosis (S1). This indicates minimal liver disease with no clinically significant scarring.
Liver Stiffness Measurement (6.8 kPa) - Fibrosis Interpretation
Your liver stiffness of 6.8 kPa falls well below the threshold for significant fibrosis and indicates F0-F1 (no to minimal fibrosis).
Evidence-Based Thresholds
- For NAFLD/MASLD patients, the established cutoff to rule out significant fibrosis (≥F2) is <8.0 kPa, with a 93% sensitivity to exclude advanced fibrosis 1, 2
- Your measurement of 6.8 kPa is below this threshold, reliably excluding clinically significant fibrosis 1
- The optimal cutoff for detecting F≥F2 in NAFLD is 8.2 kPa (rounded to 8.0 kPa clinically), and you are well below this 3
- For hepatitis B, the cutoff for F2-4 is 6.9-7.3 kPa, and you are at the lower end of this range 1
Fibrosis Stage Classification
- F0-F1 (no to minimal fibrosis): <8.0 kPa 1, 2
- F≥F2 (significant fibrosis): ≥8.0-8.2 kPa 1, 3
- F≥F3 (advanced fibrosis): ≥9.6-10.8 kPa 1, 3
- F4 (cirrhosis): ≥12.0-13.6 kPa 1, 3
Your 6.8 kPa measurement places you in the F0-F1 category with high confidence 1, 3
Controlled Attenuation Parameter (202 dB/m) - Steatosis Interpretation
Your CAP of 202 dB/m indicates minimal to no steatosis (S0-S1).
Evidence-Based CAP Thresholds
- S≥S1 (any steatosis): ≥248-302 dB/m 1, 3
- S≥S2 (moderate steatosis): ≥268-331 dB/m 1, 3
- S3 (severe steatosis): ≥280-337 dB/m 1, 3
Your CAP of 202 dB/m is significantly below even the S1 threshold, indicating either no steatosis or very minimal fat accumulation that does not meet criteria for S1 3
Steatosis Grade Classification
- In the largest validation study of 450 NAFLD patients, the Youden cutoff for S≥S1 was 302 dB/m 3
- Another multicenter study found S≥S2 cutoffs of 267-273 dB/m depending on probe type 4
- Your measurement of 202 dB/m is 100+ dB/m below the threshold for even mild steatosis 3, 4
Clinical Implications and Management
You are at low risk for liver-related complications and can be managed with surveillance testing in 2-3 years 1, 2
Recommended Follow-Up
- Repeat FibroScan in 2-3 years if metabolic risk factors persist (obesity, diabetes, metabolic syndrome) 1, 2
- Repeat in 3-5 years if risk factors are well-controlled 2
- No urgent hepatology referral needed, as LSM <8.0 kPa reliably excludes advanced fibrosis 1, 2
Important Caveats
- These results assume your FibroScan met technical validity criteria: ≥10 successful measurements, success rate ≥60%, and interquartile range <30% of median value 2, 5
- Recent food intake (within 4 hours), active inflammation, or recent alcohol use can falsely elevate readings 2, 5
- If you have chronic hepatitis B or C, different management algorithms apply even with low LSM 2
What This Means for Your Liver Health
- No clinically significant liver scarring detected 1, 3
- Minimal to no fat accumulation in the liver 3, 4
- Low risk for progression to cirrhosis or liver-related complications 1, 6
- Continue addressing any underlying metabolic risk factors (weight, diabetes control, alcohol use) to maintain this favorable status 1